Terms: = Colorectal cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
84 results:
1. Multifaceted effects of LRP6 in cancer: exploring tumor development, immune modulation and targeted therapies.
Li L; Zhao L; Yang J; Zhou L
Med Oncol; 2024 Jun; 41(7):180. PubMed ID: 38898247
[TBL] [Abstract] [Full Text] [Related]
2. Anti-HSP70 alleviates cell migration and proliferation in colorectal cancer cells (CRC) by targeting cxcr4 (in vitro study).
Alsaab HO; Almalki AH
Med Oncol; 2023 Jul; 40(9):256. PubMed ID: 37516711
[TBL] [Abstract] [Full Text] [Related]
3. Activin and Hepatocyte Growth Factor Promotes colorectal cancer Stemness and Metastasis through FOXM1/SOX2/cxcr4 Signaling.
Peng H; Ye T; Deng L; Yang X; Li Q; Tong J; Guo J
Gut Liver; 2024 May; 18(3):476-488. PubMed ID: 37458065
[TBL] [Abstract] [Full Text] [Related]
4. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
5. Impact of cxcr4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract] [Full Text] [Related]
6. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.
Hewavisenti RV; Arena J; Ahlenstiel CL; Sasson SC
Front Immunol; 2023; 14():1112513. PubMed ID: 36960048
[TBL] [Abstract] [Full Text] [Related]
7. Sequential treatment with Activin and Hepatocyte Growth Factor Induces FOXM1 to Promote colorectal cancer Liver Metastasis.
Peng H; Ye T; Deng L; Yang X; Jiang Z; Guo J
Can J Gastroenterol Hepatol; 2022; 2022():8996203. PubMed ID: 36591565
[TBL] [Abstract] [Full Text] [Related]
8. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer.
Jia Y; Yan Q; Zheng Y; Li L; Zhang B; Chang Z; Wang Z; Tang H; Qin Y; Guan XY
J Exp Clin Cancer Res; 2022 Sep; 41(1):287. PubMed ID: 36171622
[TBL] [Abstract] [Full Text] [Related]
9. GSDMD-dependent pyroptotic induction by a multivalent cxcr4-targeted nanotoxin blocks colorectal cancer metastases.
Sala R; Rioja-Blanco E; Serna N; Sánchez-García L; Álamo P; Alba-Castellón L; Casanova I; López-Pousa A; Unzueta U; Céspedes MV; Vázquez E; Villaverde A; Mangues R
Drug Deliv; 2022 Dec; 29(1):1384-1397. PubMed ID: 35532120
[TBL] [Abstract] [Full Text] [Related]
10. Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5‑FU by promoting the SDF‑1/cxcr4/Akt axis.
Zhao Q; Long Y; Cheng W; Huang Y; Li J; Li Y; Li X; Guo X; Li Y; Li G; Gong K; Zhang J
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35506454
[TBL] [Abstract] [Full Text] [Related]
11. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract] [Full Text] [Related]
12. Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors.
Xu L; Cai Y; Chen X; Zhu Y; Cai J
BMC Cancer; 2021 Sep; 21(1):989. PubMed ID: 34479528
[TBL] [Abstract] [Full Text] [Related]
13. CircN4BP2L2 promotes colorectal cancer growth and metastasis through regulation of the miR-340-5p/cxcr4 axis.
Yang KD; Wang Y; Zhang F; Luo BH; Feng DY; Zeng ZJ
Lab Invest; 2022 Jan; 102(1):38-47. PubMed ID: 34326457
[TBL] [Abstract] [Full Text] [Related]
14. CXCL12-cxcr4/CXCR7 Axis in colorectal cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract] [Full Text] [Related]
15. CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.
Lepsenyi M; Algethami N; Al-Haidari AA; Algaber A; Syk I; Rahman M; Thorlacius H
Clin Exp Metastasis; 2021 Aug; 38(4):401-410. PubMed ID: 34115261
[TBL] [Abstract] [Full Text] [Related]
16. A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant treatment in Locally Advanced Rectal cancer.
Dalle Fratte C; Mezzalira S; Polesel J; De Mattia E; Palumbo A; Buonadonna A; Palazzari E; De Paoli A; Belluco C; Canzonieri V; Toffoli G; Cecchin E
Oncol Res; 2022 Jan; 28(9):847-855. PubMed ID: 34108073
[TBL] [Abstract] [Full Text] [Related]
17. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
18. Cisatracurium regulates the cxcr4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling.
Xia YZ; Shan GF; Yang H; Zha J; Wang L; Chen JM; Zhang XS
Chem Biol Interact; 2021 Apr; 339():109424. PubMed ID: 33617803
[TBL] [Abstract] [Full Text] [Related]
19. The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable
Kalbkhani F; Pirnejad A; Sam S; Sam MR
Nutr Cancer; 2021; 73(11-12):2654-2664. PubMed ID: 33283545
[TBL] [Abstract] [Full Text] [Related]
20. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene cxcr4, stem cell regulatory genes and self-renewal.
Sarkhosh-Inanlou R; Imani M; Sam MR
Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
[TBL] [Abstract] [Full Text] [Related]
[Next]
